Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
P/E ratio for Aprea Therapeutics, Inc. (APRE)
P/E ratio as of 2023: -1.19
According to Aprea Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.19. At the end of 2022 the company had a P/E ratio of 0.00.
P/E ratio history for Aprea Therapeutics, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.19 |
| 2022 | 0.00 |
| 2021 | -1.67 |
| 2020 | -1.93 |
| 2019 | -34.93 |
| 2018 | -18.58 |
| 2017 | -19.00 |